Pfizer Inc. (NYSE:PFE) welcomes today’s announcement from the GAVI Alliance regarding the signing of a new supply agreement for Pfizer to provide additional doses of Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]), the company’s 13-valent pneumococcal conjugate vaccine, for use in infants and young children to help protect against pneumococcal disease 1 in the world’s poorest countries under the terms of the Advance Market Commitment (AMC). Pneumococcal disease is one of the leading causes of vaccine-preventable deaths worldwide in children younger than 5 years of age. 2 Prevenar 13 is a vaccine that helps protect against the 13 strains of pneumococcal disease that are included in the vaccine. In the United States, it is known as Prevnar 13 and is used for the prevention of invasive pneumococcal disease in infants and young children. The AMC is an innovative public health financing mechanism designed to accelerate global rollout of vaccines in the world’s poorest countries and is administered by the GAVI Alliance, a global health partnership committed to saving children’s lives by increasing access to immunization. Under the terms of the new supply agreement, Pfizer has committed to supply the United Nations Children's Fund (UNICEF) with up to 260 million doses of Prevenar 13, at a reduced tail price, over the course of the agreement period (through 2025). This is in addition to 480 million doses of the vaccine already committed through the first two Supply Agreements. The tail price is the reduced price per dose set by the manufacturer and paid by GAVI; the remaining amount is paid by the AMC. Pfizer will offer Prevenar 13 through the AMC at the reduced price of $3.40 per dose for the remainder of this year, at which time the price will further decrease to $3.30 per dose for the remainder of the agreement. This pricing will apply to doses purchased under all AMC Supply Agreements.